TNFRSF9 and non-small cell lung carcinoma: CD137+ T cells were considered tumor-specific, and recently, we demonstrated that this cellular subset evaluated before therapy was an independent prognostic factor in advanced NSCLC patients who underwent immunotherapy as the first line (16).